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Summary objective In 2004, Sierra Leone adopted artesunate plus amodiaquine as ﬁrst-line antimalarial
treatment. We evaluated the efﬁcacy of this combination in Kailahun, where a previous study had shown
70.2% efﬁcacy of amodiaquine in monotherapy.
methods Method and outcome classiﬁcation of the study complied with WHO guidelines. Children
6–59 months with uncomplicated malaria were followed-up for 28 days. PCR genotyping was used to
distinguish recrudescence from reinfection. Reinfections were reclassiﬁed as cured.
results Of 172 children who were referred to the study clinic, 126 satisﬁed inclusion criteria and were
enrolled. No early treatment failures were reported. The day 14, efﬁcacy was 98.2% (95% CI:
93.8–99.8). Of 65 recurrent parasitaemias analysed by PCR, 17 were recrudescences. The PCR-adjusted
day 28 efﬁcacy was 84.5% (95% CI: 76.4–90.7). All true failures occurred in the last 8 days of follow-
up. Of 110 children who completed the 28-day follow-up, 54 (49.1%) experienced a novel infection.
conclusion The efﬁcacy of this combination was disappointing. The high reinfection rate suggested
little prophylactic effect. In Kailahun a more efﬁcacious combination might be necessary in the future.
The efﬁcacy of AS + AQ needs to be monitored in Kailahun and in the other regions of Sierra Leone.
keywords Plasmodium falciparum, artemisinin combination therapies, artesunate, amodiaquine, in vivo
efﬁcacy, Sierra Leone
Introduction
In 2002–2003, a multicentric antimalarial efﬁcacy study
was carried out in Sierra Leone by Checchi and colleagues
(2005). This study demonstrated the low overall efﬁcacy of
both ﬁrst- and second-line antimalarial drugs, chloroquine
(CQ) and sulfadoxine-pyrimethamine (SP). The efﬁcacy of
amodiaquine (AQ), the third monotherapy tested, varied
within the country, ranging from 94.6% to 70.2%. The
lowest efﬁcacy was reported in Kailahun (Checchi et al.
2005).
In 2004, the Ministry of Health and Sanitation, follow-
ing WHO recommendations (WHO/RBM 2003), adopted
artesunate plus AQ (AS + AQ) as ﬁrst-line antimalarial
treatment and artemether plus lumefantrine (Coartem )a s
second-line. AS + AQ was expected to be highly efﬁcacious
(Adjuik et al. 2002) and well tolerated (Adjuik et al.
2004). However, the high efﬁcacy of AS + AQ, that would
expect with the introduction of a new treatment, could not
be guaranteed in Kailahun, given the relatively low efﬁcacy
of monotherapy AQ in the previous year. In 2004 we
assessed, therefore, the in vivo efﬁcacy of AS + AQ in
Kailahun. We report here the study results.
Methods and materials
The study took place at the outpatient department of
Me ´decins Sans Frontie `res (MSF) hospital in Kailahun town
(Figure 1). This structure also hosted the previous study
and we followed the same protocol (Checchi et al. 2005),
as summarized below.
Eligibility for inclusion and clinical and parasitological
evaluation were according to WHO recommendations
(WHO 1996). Children aged 6–59 months with conﬁrmed
uncomplicated Plasmodium falciparum malaria and meet-
ing inclusion criteria were enrolled, treated on site with
3-day artesunate, 4 mg/kg/day (Arsumax , Sanoﬁ Win-
throp AMO, Gentilly, France), and amodiaquine, 10 mg/
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followed-up for a period of 28 days.
Based on available data on the gain in efﬁcacy when AS
is added to AQ, and the known failure of AQ in Kailahun
(29.8%), 15% failure was hypothesized for AS + AQ. A
size of 126 children was estimated; assuming a 95%
signiﬁcance level (precision of ± 7.5%); taking in account
20% possible withdrawals; and, 20% expected reinfections
occurring during follow-up.
Both thick and thin blood smears were taken from
enrolled patients on day 0, 2, 3, 7, 14, 21, 28 and any other
day if needed. Microscopic examination was done under
100· oil immersion magniﬁcation. A physician examined
the child’s clinical condition during the entire follow-up
period.
All therapeutic failures received a rescue treatment
consisting of oral quinine hydrochloride, 8 mg/kg every 8 h
for 7 days, or artemether intramuscular, 3.2 mg/kg loading
dose, followed by 1.6 mg/kg/day for at least 3 days, when
oral intake was not possible. All children received anti-
helmintic (mebendazole 250 mg or albendazole 400 mg).
Children with initial haemoglobin below 10 g/dl received
ferrous sulphate 30 mg/kg/day for 2 months and folic acid
5 mg/day, starting from day 7 for 1 month.
Gametocyte carriage was measured on days 0, 3, 7, 14,
21 and 28. Haemoglobin levels were measured on day 0,
14 and 28 with the Lovibond undiluted colorimetric
technique (Lovibond, Assistant Co. Sondheim Rhon,
Germany). Children were considered non anaemic when
haemoglobin was ‡ 11.0 g/dl, mildly anaemic when hae-
moglobin was ‡8 and <11.0 g/dl, and moderately anaemic
when haemoglobin was ‡5 and <8.0 g/dl.
PCR genotyping, using msp-1 and msp-2 markers, was
applied to distinguish true recrudescences, due to treatment
failure, from episodes of reinfection (WHO 2002). Recru-
descence was identiﬁed when pre- and post-treatment
sample alleles were the same; re-infection was identiﬁed
when pre- and post-treatment sample alleles were distinct;
and mixed recrudescence and re-infection when similar
pre- and post-treatment samples alleles were found, but
with additional distinct alleles identiﬁed. Analysis was
carried out at the Laboratory of Parasitology and Mycol-
ogy of Avicenne Hospital, Bobigny (France), using a
published method (Ranford-Cartwright et al. 1997;
Snounou et al. 1999).
Data were double entered and validated using EpiData
(The EpiData Association, Odense, Denmark) and analysed
using Stata 8.0 (College Station, TX). Total number of
failures (early treatment failure + late clinical failure + late
parasitological failure [ETF + LCF + LPF]) were calculated
over the total number of analysable outcomes, and
expressed as a percentage with associated 95% conﬁdence
intervals. During the 28-day follow-up, treatment failures,
which were conﬁrmed to be recrudescence or mixed
recrudescence/reinfection by PCR genotyping, were classi-
ﬁed as true failures, while pure reinfections were reclassiﬁed
as adequate clinical and parasitological response (ACPR).
Although the reclassiﬁcation of reinfection as ACPR was no
longer recommended (WHO 2003), we kept this method to
compare our results with those of the previous multi-centric
study (Checchi et al. 2005). Patients for which the PCR
result wasinconclusive (indeterminate or noDNAisolated),
secondary exclusions and patients lost to follow-up were
excluded from the analysis.
The failure proportion on day 14 (without PCR adjust-
ment) was also calculated. Haemoglobin levels on day
0 and day 28 were compared (McNemar’s test).
The Ethics Committee of the Ministry of Health and
Sanitation of Sierra Leone approved the study protocol.
Results
Between 14 July and 26 August 2004, of 172 children aged
6–59 months admitted to the clinic, 126 satisﬁed the
inclusion criteria, and were enrolled in the study. The male/
female ratio was 0.75 (54/72). Other baseline character-
istics are described in Table 1. Three children, although
able to drink or breast feed, did not complete the treatment
because of repeated vomiting of the drugs; 10 children
were also withdrawn because of a concomitant illness
requiring hospitalization (n ¼ 8) or because of other
Figure 1 1 Location of study site.
Tropical Medicine and International Health volume 11 no 7 pp 1017–1021 july 2006
F. Grandesso et al. In vivo efﬁcacy of artesunate plus amodiaquine in Kailahun, Sierra Leone
1018 ª 2006 Blackwell Publishing Ltdantimalarial intake (n ¼ 2). Sixty-ﬁve children were found
parasitaemic during follow-up (2 before and 63 after day
14) requiring PCR genotyping. Of these, one sample had
no DNA ampliﬁed; 17 were treatment failures (10 simple
recrudescence and 7 mixed recrudescences and reinfec-
tions); and 47 were pure reinfections. A novel infection
(considering mixed recrudescence/reinfection and pure
reinfection) was detected in 49.1% of children (54/110)
(Table 2).
Day 14 therapeutic efﬁcacy was 98.2% (112/114, 95%
CI: 93.8–99.8) (Table 3), while day 28 PCR-adjusted
therapeutic efﬁcacy was 84.5% (93/110, 95% CI:
76.4–90.7). All true failures occurred in the last 8 days of
follow-up. No early treatment failures were reported.
Fever clearance on day 2 (<37.5  C) and parasite
clearance on day 3 were 95.2% (119/125) and 94.2%
(114/121) respectively. Haemoglobin recovery was as-
sessed among the 87 children who attended for their day
28 visit. Among the 80 children anaemic on day 0 (71
mildly and 9 moderately anaemic), 27 (33.7%) were no
longer anaemic on day 28 (P < 0.001), regardless of the
therapeutic outcome; four children not anaemic on day
0 became moderately anaemic on day 28.
On the day of inclusion, 5.6% of children (7/126) were
reported having gametocytes. The proportion increased to
11.6% (14/121) on day 7 and progressively decreased
(Figure 2) until day 28 when none of the children were
gametocytaemic.
Discussion
The results until day 14 were extremely promising.
AS + AQ resulted in a high day 2 fever clearance and a
high day 3 parasite clearance, which has been shown in
previous studies (Staedke et al. 2004; Hamour et al. 2005).
No early treatment failures were reported and therapeutic
efﬁcacy on day 14 was also very high (98.2%). The day 28
efﬁcacy (84.5%), nevertheless, conﬁrmed expectations and
fears, given the already low efﬁcacy of the monotherapy
AQ the previous year (Checchi et al. 2005). These results
questioned whether AS + AQ is suitable ﬁrst-line treatment
in Kailahun. Low efﬁcacies of this combination have also
been recently reported in Africa (Rwagacondo et al. 2004)
and in Asia (Durrani et al. 2005).
On one hand, AS + AQ would undoubtedly contribute
to a general improvement of malaria case management,
Table 2 PCR genotyping results
n ¼ 64
n %
Total PCR result available
Recrudescence (A) 10 15.6
Mixed recrudescence and reinfection (B) 7 10.9
Reinfection (C) 47 73.4
Total conﬁrmed treatment failure (A + B) 17 26.6
Total reinfection (B + C) 54
Table 1 Patient characteristics at inclusion
Age (months), median (IQR) 17 10–24
Gender ratio (M/F) 0.75 54/72
Asexual parasite density (/ll),
geometric mean (IQR)
27 116 10 630–68 870
Parasitaemia > 10 000/ll, n (%) 96 76.2
Temperature ( C), median (IQR) 39.0 38.3–39.4
MUAC, median (IQR) 148 142–156
Haemoglobin, n (%)
No anaemia (Hb ‡ 11 g/dl) 12 9.5
Mild anaemia (Hb 8–10.9 g/dl) 99 78.6
Moderate anaemia
(Hb 5–7.9 g/dl)
15 11.9
IQR, Inter-quartile range; MUAC, middle-upper arm circumfer-
ence.
Table 3 Day 14 and PCR-adjusted day 28 therapeutic responses
Outcomes
Day 14 (n ¼ 114) Day 28 (n ¼ 110)
n % 95% CI n % 95% CI
ETF 0 0.0 0.0–3.2* 0 0.0 0.0–3.3*
LCF 0 0.0 0.0–3.2* 9 8.2 3.8–15.0
LPF 2 1.8 0.2–6.2 8 7.3 3.2–13.8
Total failures 2 1.8 0.2–6.2 17 15.5 9.3–23.6
ACPR 112 98.2 93.8–99.8 93 84.5 76.4–90.7
*One-side, 97.5% CI; ETF, Early Treatment Failure; LCF,
Late Clinical Failure, LPF, Late Parasitological Failure; ACPR,
Adequate Clinical and Parasitological Response.
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Figure 2 Proportion of children with gametocytes on different
days of follow-up.
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were treated with ineffective drugs. The day 28 failures
were almost half of those that occurred with monotherapy
AQ (15.5% vs. 29.2%) (Checchi et al. 2005); on day 28 no
children were reported carrying gametocytes; and a con-
siderable number reported improved haemoglobin level,
even if this was probably the result of the combined effect
of having recovered from malaria and the beneﬁt of
antihelmintic and supportive treatments.
On the other hand, the day 28 efﬁcacy was far from
what we would expect from a newly introduced treatment,
and the high reinfection rate suggested that this combina-
tion provided little prophylactic effect. The maintenance of
the current efﬁcacy over time needs to be monitored and
we cannot exclude that an alternative treatment might be
necessary in the near future in Kailahun. Alternatives,
however, are few. Artemether plus lumefantrine
(Coartem ), the current second-line treatment, is highly
efﬁcacious in Africa (Mutabingwa et al. 2005; Piola et al.
2005), but it is currently more expensive than AS + AQ.
Little information is yet available about the long term
effects of the large scale use of ACTs in Africa. It is hoped
that, as in Thailand (Brockman et al. 2000), the use of a
drug in combination with an artemisinin slows the resist-
ance process. The long-term positive results in Asia, though
obtained in lower transmission settings, are encouraging.
Further studies to monitor the efﬁcacy of AS + AQ are
necessary in Kailahun and in other regions of the country.
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Faible efﬁcacite ´ de la combinaison arte ´sumate plus amodiaquine dans le traitement de la malaria non complique ´e chez les enfants de moins de 5
ans a ` Kailahun en Sierra Leone
objectifs En 2004, la Sierra Leone a adopte la combinaison arte ´sunate + amodiaquine comme traitement de premie `re ligne de la malaria. Nous avons
e ´value ´ l’efﬁcacite ´ de cette combinaison a ` Kailahun, ou ` une pre ´ce ´dente e ´tude avait de ´montre ´ une efﬁcacite ´ de 70,2% pour l’amodiaquine en mono-
the ´rapie.
me ´thodes Me ´thode et classiﬁcation des re ´sultats ont e ´te ´ re ´alise ´es selon les directives de l’OMS. Les enfants de 6 a ` 59 mois avec une malaria non
complique ´e ont e ´te ´ suivis pendant 28 jours. Un ge ´notypage par PCR a e ´te ´ utilise ´ pour distinguer recrudescence et re ´infection. Les cas de re ´infections ont
e ´te ´ reclassiﬁe ´s comme cas gue ´ris.
re ´sultats Sur 176 enfants re ´fe ´re ´sa ` la clinique d’e ´tude, 126 satisfaisaient aux crite `res d’inclusions et ont e ´te ´ enro ˆle ´s. Aucun e ´chec de traitement n’a e ´te ´
rapporte ´ au de ´but de l’e ´tude. L’efﬁcacite ´ au jour 14 e ´tait de 98,2% (IC95%: 93,8–99,8). Sur 65 cas de parasite ´mie re ´currente qui ont e ´te ´ analyse ´sp a r
PCR, 17 se sont ave ´re ´se ˆtre de vraies recrudescences. L’efﬁcacite ´ au jour 14, ajuste ´e par les re ´sultats de PCR e ´tait de 84,5% (IC95%: 76,4–90,7). Tous
les cas d’e ´chec re ´el sont survenus dans les 8 derniers jours du suivi. Sur 110 enfants qui ont comple ´te ´ le suivi de 28 jours, 54 (49,1%) ont subi une
nouvelle infection.
conclusions L’efﬁcacite ´ de la combinaison e ´tait de ´cevante. Le taux e ´leve ´ des re ´infections sugge `re un faible effet prophylactique. A Kailahun, une
combinaison plus efﬁcace reste ne ´cessaire, quoique, peu d’alternatives soient disponibles en ce moment. L’efﬁcacite ´ de la combinaison arte ´sunate plus
amodiaquine devrait e ˆtre suivie a ` Kailahun et dans d’autres re ´gions de la Sierra Leone.
mots cle ´s Plasmodium falciparum,t h e ´rapies de combinaison a ` l’artemisinine, arte ´sunate, amodiaquine, efﬁcacite ´ in vivo, Sierra Leone
Baja eﬁcacia de la combinacio ´n de artesunato con amodiaquina para el tratamiento de malaria por falciparum no complicada entre nin ˜os menores
de 5 an ˜os en Kailahun, Sierra Leone
objetivo: En el 2004, Sierra Leona adopto ´ el artesunato ma ´s amodiaquina como primera lı ´nea de tratamiento para malaria. Evaluamos la eﬁcacia de
esta combinacio ´n en Kailahun, en donde un estudio previo habı ´a demostrado una eﬁcacia de la amodiaquina en monoterapia del 70.2%.
me ´todos: La metodologı ´a y la clasiﬁcacio ´n de los resultados cumplı ´an con las directrices de la OMS. Los nin ˜os entre 6 y 59 meses, con malaria no
complicada, fueron seguidos durante 28 dı ´as. Se utilizo ´ el genotipaje mediante PCR para distinguir entre reinfeccio ´n y recrudecimiento. Las re-
infecciones fueron clasiﬁcadas como curados.
resultados: De 172 nin ˜os derivados a la clı ´nica del estudio, 126 satisfacı ´an los criterios de inclusio ´n y entraron en el estudio. No se reportaron fallas
terape ´uticas tempranas. La eﬁcacia a los 14 dı ´as fue del 98.2% (95% CI: 93.8–99.8). De 65 parasitemias recurrentes analizadas por PCR, 17 eran
recrudescencias. La eﬁcacia a dı ´a 28, ajustada por PCR, fue del 84.5% (95% CI: 76.4–90.7). Todas los fallos verdaderos ocurrieron durante los u ´ltimos
8d ı ´as de seguimiento. De 110 nin ˜os que terminaron los 28 dı ´as de seguimiento, 54 (49.1%) experimentaron una infeccio ´n nueva.
conclusio ´n: La eﬁcacia de esta combinacio ´n fue decepcionante. La alta tasa de reinfeccio ´n sugiere poco efecto proﬁla ´ctico. En Kailahun se requiere
una combinacio ´nm a ´s eﬁcaz, aunque actualmente existen pocas alternativas disponibles. La eﬁcacia de AS + AQ requiere monitorizacio ´n tanto en
Kailahun como en otras regiones de Sierra Leona.
palabras clave Plasmodium falciparum, terapia de combinacio ´n con artemisininas, artesunato, amodiaquina, eﬁcacia in vivo, Sierra Leona
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